Bank of New York Mellon Corp Acquires Shares of 219,661 Emergent Biosolutions Inc. $EBS

Bank of New York Mellon Corp purchased a new stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 219,661 shares of the biopharmaceutical company's stock, valued at approximately $1,841,000. Bank of New York Mellon Corp owned about 0.43% of Emergent Biosolutions at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. CANADA LIFE ASSURANCE Co bought a new stake in shares of Emergent Biosolutions during the 4th quarter worth $45,000. Legal & General Group Plc purchased a new stake in Emergent Biosolutions during the second quarter worth about $31,000. Raymond James Financial Inc. purchased a new stake in Emergent Biosolutions during the second quarter worth about $53,000. Kemnay Advisory Services Inc. bought a new stake in Emergent Biosolutions in the fourth quarter worth about $107,000. Finally, Abel Hall LLC bought a new stake in Emergent Biosolutions in the fourth quarter worth about $129,000. 78.40% of the stock is currently owned by institutional investors.

Insider Activity at Emergent Biosolutions

In other news, SVP Paul Williams sold 3,000 shares of the company's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the transaction, the senior vice president owned 159,098 shares of the company's stock, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on EBS shares. JPMorgan Chase & Co. initiated coverage on Emergent Biosolutions in a report on Friday, August 21st. They set an "underweight" rating for the company. Zacks Research upgraded Emergent Biosolutions to a "hold" rating in a research note on Tuesday, August 11th. UBS Group reaffirmed a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings upgraded Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a research note on Friday, August 21st. Finally, Benchmark reissued a "buy" rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $10.00.

Emergent Biosolutions Price Performance

Shares of NYSE EBS opened at $6.00 on Wednesday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. Emergent Biosolutions Inc. has a fifty-two week low of $4.36 and a fifty-two week high of $14.06. The stock has a market cap of $307.88 million, a PE ratio of -1.69 and a beta of 2.34. The stock has a fifty day moving average of $6.60 and a 200-day moving average of $7.83.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.68. The business had revenue of $234.30 million for the quarter, compared to analysts' expectations of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. Equities research analysts anticipate that Emergent Biosolutions Inc. will post 0.13 earnings per share for the current year.

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc. (NYSE:EBS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.